1. Home
  2. XBIT vs III Comparison

XBIT vs III Comparison

Compare XBIT & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.44

Market Cap

75.0M

Sector

Health Care

ML Signal

HOLD

Logo Information Services Group Inc.

III

Information Services Group Inc.

HOLD

Current Price

$4.22

Market Cap

203.8M

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIT
III
Founded
2005
2006
Country
United States
United States
Employees
N/A
1500
Industry
Pharmaceuticals and Biotechnology
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
75.0M
203.8M
IPO Year
2015
2006

Fundamental Metrics

Financial Performance
Metric
XBIT
III
Price
$2.44
$4.22
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$5.50
AVG Volume (30 Days)
21.3K
211.1K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
4.46%
EPS Growth
N/A
216.67
EPS
N/A
0.05
Revenue
N/A
$192,745,000.00
Revenue This Year
N/A
$3.85
Revenue Next Year
N/A
$4.34
P/E Ratio
N/A
$82.70
Revenue Growth
N/A
4.51
52 Week Low
$2.09
$3.74
52 Week High
$3.61
$6.45

Technical Indicators

Market Signals
Indicator
XBIT
III
Relative Strength Index (RSI) 40.06 53.63
Support Level $2.15 $4.12
Resistance Level $2.49 $4.37
Average True Range (ATR) 0.06 0.16
MACD -0.02 0.01
Stochastic Oscillator 4.17 64.77

Price Performance

Historical Comparison
XBIT
III

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About III Information Services Group Inc.

Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.

Share on Social Networks: